Beyond its effect on PI3K/Akt/mTOR and Ras/Raf/ERK pathways, linsitinib modulates ABC transporter-mediated multidrug resistance, increasing the accumulation of substrate anti-cancer drugs inside the cells. Here, AKT1 is linked to cancer.